ArticleDiscover oncology2025
Adherence to chemotherapy and associated factors among adult patients with cancer in the Amhara region, Ethiopia, 2022.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdherence to chemotherapy treatment requires collaboration and sincere agreement between healthcare providers and patients. Poor medication adherence is problematic as it can lead to reduced effectiveness of the treatment. Poor survival, a rise in relapses, treatment failure, and higher healthcare expenses will result from this. A measure of patient treatment adherence is crucial to attain ideal results, such as curative treatment or improving quality of life.
objectiveTo assess cancer patients' adherence to chemotherapy and related factors patients in the Amhara Region, Ethiopia, in 2022. METHODS AND MATERIALS: Between May 28, 2022, and June 22, 2022, 460 cancer patients in the Amhara region participated in a cross-sectional study carried out by systematic randomized sampling. Data were gathered using an interview-based, previously approved questionnaire. For analysis, the data were first imported into Epi-Data version 4.6 and then exported to the Statistical Package for Social Science version 26. Variables with a p-value of 0.25 were evaluated in a bivariate logistic regression to select a candidate variable for multivariate logistic regression. Variables with a p-value less than 0.05 were deemed significantly associated factors in multivariable logistic regression, and the resulting AOR and 95% CI are displayed for those variables. The Hosmer Lemeshow test was used to confirm the model's appropriateness, and multi-collinearity was verified with a standard error.
resultsThe proportion of good adherence in the Amhara region is 42.3% (95%CI [37.6-47.6]). A history of comorbidity [AOR = 2.74, 95% CI (1.56, 4.81)], no serious side effects from chemotherapy [AOR = 3.50, 95% CI (1.55, 7.90)], having social support [AOR = 1.52, 95% CI (1.21, 1.95)], being a woman [AOR = 2.17, 95% CI (1.31, 3.60)], and having a family history of cancer [AOR = 3.58, 95% CI (2.22, 5.76)], were associated with good chemotherapy adherence. CONCLUSION AND RECOMMENDATIONS: Compared to other studies, the proportion of poor adherence in the Amhara region was high. Health professionals, families, and government representatives should all work together to provide social support and other systems that will lessen the likelihood that cancer patients with comorbidities may have side effects from chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.